• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/12/25 6:30:44 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    false 0001819576 0001819576 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 12, 2025

     

    LIQUIDIA CORPORATION
    (Exact name of registrant as specified in its charter)
         
    Delaware 001-39724 85-1710962
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

     

    419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (919) 328-4400 

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock LQDA The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

      

    Item 2.02 Results of Operations and Financial Condition.

     

    On August 12, 2025, Liquidia Corporation, a Delaware corporation, issued a press release announcing its financial results for the quarter ended June 30, 2025, and also provided a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.*

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d)

     

    Exhibit
    No.
      Exhibit
    99.1   Press Release of Liquidia Corporation, dated August 12, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    * The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    August 12, 2025 Liquidia Corporation
       
      By: /s/ Michael Kaseta
        Name: Michael Kaseta
        Title: Chief Financial Officer and Chief Operating Officer

     

     

     

    Get the next $LQDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    8/15/2025$43.00Buy
    Jefferies
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    1/5/2024$18.00 → $28.00Buy
    Needham
    More analyst ratings

    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and COO Kaseta Michael sold $600,132 worth of shares (30,000 units at $20.00), decreasing direct ownership by 7% to 376,412 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    8/7/25 4:30:09 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Adair Jason sold $8,871 worth of shares (454 units at $19.54), decreasing direct ownership by 0.23% to 193,180 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    7/30/25 4:31:13 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Boyle Dana sold $20,771 worth of shares (1,063 units at $19.54), decreasing direct ownership by 0.57% to 186,105 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    7/30/25 4:30:14 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern

    8/12/25 6:30:45 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

    MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

    8/5/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

    MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Middle District of North Carolina denying United Therapeutics Corporation's request for a preliminary injunction and temporary restraining order in its complaint filed against Liquidia and the first commercial sale of YUTREPIA™ (treprostinil) inhalation powder. Michael Kaseta, Liquidia's Chief Financial

    6/23/25 4:34:16 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/16/24 4:05:20 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/4/24 5:51:34 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    12/18/23 5:02:01 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Liquidia Technologies with a new price target

    Jefferies resumed coverage of Liquidia Technologies with a rating of Buy and set a new price target of $43.00

    8/15/25 7:59:34 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Technologies downgraded by Oppenheimer with a new price target

    Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

    5/19/25 8:49:50 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Liquidia Technologies with a new price target

    Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

    12/20/24 7:42:58 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    SEC Filings

    View All

    SEC Form 10-Q filed by Liquidia Corporation

    10-Q - Liquidia Corp (0001819576) (Filer)

    8/12/25 6:45:29 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Liquidia Corp (0001819576) (Filer)

    8/12/25 6:30:44 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    8/5/25 5:02:59 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

    SC 13G/A - Liquidia Corp (0001819576) (Subject)

    11/12/24 5:35:19 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/12/24 4:22:57 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/4/24 5:51:42 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Financials

    Live finance-specific insights

    View All

    Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern

    8/12/25 6:30:45 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

    MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

    8/5/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

    MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

    5/1/25 8:00:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Leadership Updates

    Live Leadership Updates

    View All

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

    GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

    10/2/23 7:00:00 AM ET
    $EBS
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

    7/21/22 4:30:00 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care